EDS ECHO Event Series: Vascular Ehlers-Danlos-Syndrome (vEDS) –
A Comprehensive Conference on Care for Individuals with vEDS
July 30-31, 2021
Scientific Chair: Dr. Sherene Shalhub
Community and Healthcare Professionals Event
The recordings from this event can now be viewed here.
In support of improving patient care, this activity has been planned and implemented by The Ehlers-Danlos Society and Project ECHO®. Project ECHO® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Designation Statement
Project ECHO® designates this live activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Project ECHO®, in compliance with the ACCME Standards of Commercial Support, requires anyone who is in a position to control the content of an activity discloses all relevant financial relationships they have had within the last 12 months with a commercial interest related to the content of the activity. The Planners and Presenters of this activity disclose that they have no financial relationships with any commercial interest. Professor Lara Bloom, Stacey Simmonds, Sacha Aziz, Dr. Alan Hakim, Dr. Sherene Shalhub, Lauren Puryear, Duncan Baker, Neeti Ghali, Dr. Peter Byers, Dr. Glenda Sobey, Dr. Fleur Van Dijk, Lianne Barret, Dr. Siddarth Prakash, Katie Wright, Dr. Xavier Jeunemaitre, Dr. Enid Neptune, Dr. Jessica A. Zagory, Dr. Laura Pace, Dr. Satish Raj, Dr. Manjit Matharu, Dr. Melissa Russo, Dr. Shaine Morris, Jared Griffin, Dr. Rohith Jesudas, Dr. Sheila Coogan, Dr. John Ohman, Dr. Amani Politano, Dr. Daphne Fulton, Dr. Stephanie Wallace, Dr. Jessica Bos, Dr. Hal Dietz.
Thank You To Our Event Sponsors!
Aytu BioPharma is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products. The company’s primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. Aytu markets ADHD products Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING). The company’s other pediatric products include Karbinal® ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. The company’s evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. As Aytu continues this trajectory, the company is building a complimentary therapeutic development pipeline that will address significant unmet needs. For more information, please visit aytubio.com.
373 Inverness Parkway, Suite 206
Englewood, CO 80112 USA
Lipedema is a chronic medical condition characterized by asymmetric buildup of adipose tissue (fat) in the legs and arms that occurs almost exclusively in women. It is a common but underrecognized disorder. Lipedema may cause pain, swelling, and easy bruising and be accompanied by an unusual texture within the fat that can feel like rice, peas, or walnuts beneath the surface of the skin.
At the Lipedema Foundation, we support collaborative research that addresses the basic biology, genetics, and epidemiology of lipedema with a mission to define, diagnose and develop treatments.
Please visit our website lipedema.org to learn more about the Lipedema Foundation.
39 Lewis Street,
+1-203-489-2989 | email@example.com